Founding Platinum

Wilson Sonsini Goodrich & Rosati

Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology, life sciences, and other growth enterprises worldwide. We represent companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations, as well as the venture firms, private equity firms, and investment banks that finance and advise them. The firm’s broad range of services and practice areas are focused on addressing the principal challenges faced by the management, boards of directors, shareholders, and in-house counsel of our clients.

The firm is nationally recognized for providing high-quality services to address the legal solutions required by its enterprise and financial institution clients. Our services include corporate law and governance, public and private offerings of equity and debt securities, mergers and acquisitions, securities class action litigation, intellectual property litigation, antitrust counseling and litigation, joint ventures and strategic alliances, technology licensing and other intellectual property transactions, tax, and employee benefits and employment law, among other areas. Our distinguished international roster of clients span a wide variety of industries, including information technology, life sciences, energy and clean technology, media and entertainment, communications, retail, and financial services.



Jefferies provides insight, expertise and execution to investors, companies and government entities. We offer deep sector expertise across a full range of products and services in investment banking, equities, fixed income and wealth management in the Americas, Europe and the Middle East and Asia. As one of the largest global healthcare investment banking team, we have more than 100 healthcare bankers worldwide covering over 780 corporate clients. Jefferies Healthcare Team has a strong track record in transacting with Chinese healthcare companies in strong cross-border capabilities that connect Chinese buyers to healthcare opportunities globally. The team has global execution capabilities and a strong track record across both M&A and equity offerings, including a market leading global biotech franchise. Jefferies coverage bankers provide in-depth worldwide coverage of all healthcare subsectors, including biotech, medtech, pharmaceuticals, diagnostics, and healthcare services. Managing Directors have an average of 17 years of healthcare investment banking experience.

Founding Gold

Suzhou BioBAY

Suzhou BioBAY is the key driver of life science innovation for Suzhou Industrial Park (SIP). Nearly 500 high-tech innovative companies covering drug discovery, medical device (including IVD), biotech, CRO have been located in BioBAY. More than 10000 scientists and professionals have come to join this dynamic innovative community, including 62 talents of The Recruitment Program of Global Experts.

BioBAY is playing an active role in building an interactive and collaborative innovation ecosystem:
- Cold Spring Harbor Asia Conference Centre — cutting-edge academic resources and global technical communication
- BioTOP — one-stop professional solutions for biomedical companies, including analysis & test, GMP verification, biomaterials trading, training, etc.
- BioBAY Sangtian Island — commercialization base for high-tech drug, medical device and IVD companies
- BioBAY Changshu — top class industrial base for biomedical industry with international advanced standards

Strategic Gold

6 Dimensions Capital

6 Dimensions Capital is a leading healthcare focused investment firm with an in-depth focus and extensive coverage across China and the United States.  The firm currently has US$1.6 billion assets under management through 4 US dollar-denominated and 3 RMB-denominated funds with offices in Shanghai, Boston, Hong Kong and San Francisco. 

6 Dimensions Capital was formed in May 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures, two prominent and complementary China-U.S. healthcare investment firms. The merger has created a powerhouse that aims to fund innovation in an optimal position to capture the biggest value appreciation on both sides of the Pacific.

Supported By

BayHelix Group

BayHelix Group is a non-profit, invitation-only organization of business leaders of Chinese heritage that fosters the growth of the life sciences and healthcare industry around the Pacific Rim and beyond. Founded in 2001, BayHelix has grown to over 300 members throughout the U.S., Canada, and Greater China. The membership base covers virtually all of the world’s top pharmaceutical and biopharmaceutical companies, as well as leading services and investment firms. Over one third of the members are senior executives, over 80% have PhDs in the life sciences, and nearly half have MBAs from the leading business schools in U.S.

Supported By

Lychee Group

Our mission is simple: create the best, most innovative events to provide you with the latest business information and the greatest opportunity to network with your peers and new potential business partners.

Since 2008, Lychee Group has helped launch some of the longest running and most reputable life sciences conferences in China including: ChinaTrials: Clinical Development Leaders' Summit, China Healthcare Investment Conference (CHIC), China Medical Affairs Summit, DeviceChina, BioCentury's China Healthcare Summit and Healthcare Capital & Connections Summit (HCCS).

Supported By


Founded by industry-recognized editors, RNDer and PharmaDJ are the leading publications providing value-added analysis for pharmaceutical and biotechnology companies doing business in China. With a mission to facilitate drug R&D and regulatory science in China, we talk to regulators and key opinion leaders from industry to piece together the China market puzzle for our readers.

In Collaboration with

ChinaBio Group

Since its founding in 2007, ChinaBio® Group has created a broad platform of capabilities connecting China life science with the world. ChinaBio has helped western life science companies identify over 400 licensing and acquisition opportunities and raise over USD 500 million in funding in China.

Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 5,000 attendees.
Consulting: ChinaBio helps global life science companies to define and execute a successful strategy in China.
Capital: ChinaBio launched its first VC fund in 2014 focused on bringing Western companies and technologies to China.
Publishing: ChinaBio® Today is the most widely read online and email newsletter on China's life science industry, with over 18,000 readers.

Media Partners

BioCentury and BayHelix Present: The 6th China Healthcare Summit

BioCentury and BayHelix Present: The 6th China Healthcare Summit

China’s Globally Facing Future: How China’s healthcare pathfinders are leveraging the nation’s innovation, policy initiatives and access to capital markets in HK and domestic exchanges to build a globally facing industry.

Six years ago, the first China Healthcare Summit asked how the nation would build the “Bridge to Innovation.” In 2019, we examine how China is now actually building the Bridge to Global Healthcare. A full two-day program highlighted by dialog among China-facing biotech innovators and their globally-facing Chinese counterparts.

The China Summit is a VIP-only event for busy biopharma and life sciences executives and investors to get a first-hand look at the innovation, business and policy transformations taking place in China. The conference is THE place to meet the right Chinese investors and partners in an intimate setting.

Media Partners

BioCentury: Biopharma's Knowledge Center

BioCentury is the essential source of intelligence for a global audience of biotech and pharmaceutical company professionals, investors, researchers, service providers and industry stakeholders who demand deep industry knowledge, data-driven analysis, independent perspective and a commitment to accuracy. Our insight, trusted reporting and in-depth analysis are built on independent, objective surveillance of the biotechnology sector, producing the industry's most respected journals and data solution resources, since 1993.

Media Partners


For more than 50 years, DIA (the Drug Information Association), a non-profit association, has served as a global forum for all those involved in health care product development and life cycle management to exchange knowledge and collaborate in a neutral setting, and a unbiased forum for the exchange of information across multiple disciplines of programming and publications.

Media Partners


Founded in 2002, GBI ( is an information, applications and services company focused on the healthcare industry. It boasts a diverse portfolio of marketing intelligence solutions that enable organizations and individuals to make data-driven decisions and communicate more effectively. Over 15 years of development, GBI has built a global presence with around 200 staff across four locations in Shanghai, Beijing, São Paolo, and Washington, DC. Our first database product was launched in 2009, and we have now built a portfolio based around the flagship brands of SOURCE, DEVINT, METRIX and NAVIS, covering the markets of China, Latin America, and the United States. GBI is now a trusted provider for the pharmaceutical and medtech industries, with established long-term partnerships with multinational industry players.

Media Partners


GlobalData is a leading intelligence data and analysis company, serving over 4,000 world’s largest companies to do strategic planning and market development. We help our client make better decisions by gaining insights into competitors, evaluating  market size and attaining strategic KOL insights and analysis in both pharma and medical device markets with our fully integrated intelligence centers.

Media Partners


Lingmed promotes three leading intelligence databases for healthcare professionals in China to make better decisions. In addition, we together with our partners in Europe provide partnering services to bridge European and Chinese pharmaceuticals with biotech companies, including valuation and market monitoring reports.

Media Partners

The New Drug Founders Club

The New Drug Founders Club was founded in April, 2015, to form a network for founders of companies focusing on innovative new drug R&D and of companies providing relevant services. The club is highly prestigious in that only founders of such companies and people well-recognized for having special and major contributions to new drug R&D in China (including China R&D heads of multinational companies, R&D heads of major domestic companies, partners of VC, and other nationally recognized leaders in new drug R&D) can be admitted to the club. This feature distinguish this club from any other professional organizations in China or the world. Currently there are about 209 members in the club, with several new applications reviewed for approval every month.

Media Partners

US-CHINA Biopharma Innovation & Investment Summit

China’s biotech scene has been exploding over the past 2 years. Chinese investors are not just pouring billions into new Asian startups, they’re also jumping into global syndicates backing a new generation of startups in the US and Europe as well.

This October, we’ll be bringing top industry players in China and the US to Shanghai for the inaugural run of the US-China Biopharma Innovation and Investment Summit. For US companies, this is a chance to explore the most important emerging healthcare market in the world, with a forecast on drug innovation and a chance to meet potential partners. And you’ll hear directly from a group of headliners on both sides of the Pacific on the most important developments you need to be aware of, with a special focus on the regulatory scene.

This is a crucial year for US-China biopharma and you won't want to miss this 2-day summit we're planning for you at the Shanghai Four Seasons, located in Pudong in the ultra-modern 21st Century Tower.


Copyright © 2019 Consortium of China Healthcare. All rights reserved.